side view of scientist looking into microscope in bright research lab

Life Sciences & Healthcare


With over 150 international specialist lawyers across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your lifesciences business. We work with and have established long-term relationships with the top 100 lifesciences companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food, including the top 20 global pharmaceutical companies and nine out of the top ten global medical device companies.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. With active memberships in major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the lifesciences sector. We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice. Equally, when you need lifesciences specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

Read more Read less


Show only
Konstantin Baranov
Cham­bers Europe 2019: CMS con­firms its lead­ing po­s­i­tion...
New rules for cre­at­ing san­it­ary pro­tec­tion zones
Own­ers and op­er­at­ors of fa­cil­it­ies hav­ing an ex­cess­ive chem­ic­al, phys­ic­al or bio­lo­gic­al ef­fect on the en­vir­on­ment have un­til 15 March 2019 to sub­mit ap­plic­a­tions to the Fed­er­al Ser­vice for Sur­veil­lance on Con­sumer Rights Pro­tec­tion and Hu­man Well­being (“Rospo­treb­n­ad­zor”).
CMS con­firms its lead­ing po­s­i­tion on the Rus­si­an leg­al...
New Rus­si­an law tight­ens the pro­ced­ure for put­ting medi­cines on the...
From 29 Novem­ber 2019, medi­cines for hu­man use will no longer be put on the mar­ket based on de­clar­a­tions of com­pli­ance and cer­ti­fic­a­tion. More com­plex qual­ity con­trol re­quire­ments will be in­tro­duced. Phar­ma­ceut­ic­al com­pan­ies will have to sub­mit doc­u­ments on.
Vladimir Zenin
CMS Rus­sia has ad­vised Ovoca Bio Plc on IVIX ac­quis­i­tion
Rus­sia ad­opts re­com­mend­a­tions on drug ad­vert­ising
The Fed­er­al An­ti­mono­poly Ser­vice of Rus­sia (FAS) to­geth­er with lead­ing in­dustry as­so­ci­ations (AIPM, AR­FP and oth­ers) is­sued Re­com­mend­a­tions for ad­vert­ising over-the-counter medi­cines*, which cov­er the most com­mon vi­ol­a­tions in the field of drug ad­vert­ising,.
CMS ad­vises Gilead Sci­ences on its agree­ment with Pharm­stand­ard...
Gov­ern­ment Is­sues Brexit Tech­nic­al No­tice for Life Sci­ences
On 23 Au­gust 2018, the UK Gov­ern­ment (the "Gov­ern­ment") is­sued the first wave of its tech­nic­al pa­pers de­signed to provide guid­ance to com­pan­ies to help pre­pare for a "No Deal" Brexit. In this scen­ario, there will be no "trans­ition peri­od" but rather the UK.
The law on counter-sanc­tions now in force
New law im­proves pro­ced­ure for re­gis­ter­ing medi­cines in Rus­sia
On 15 June 2018, Fed­er­al Law No. 140-FZ “On Amend­ments to the Fed­er­al Law ‘On the Cir­cu­la­tion of Medi­cines’”* (the “Law”) came in­to force. It sim­pli­fies the re­gis­tra­tion of for­eign medi­cines, en­hances the op­por­tun­it­ies for con­tract man­u­fac­tur­ing in Rus­sia and.
New rules for de­scrib­ing medi­cines for pub­lic pro­cure­ment:...
New rules for de­scrib­ing medi­cines for pub­lic pro­cure­ment: more com­pet­i­tion...
The new rules* for de­scrib­ing medi­cines in tender doc­u­ment­a­tion for the pro­cure­ment of drugs by the state and mu­ni­cip­al au­thor­it­ies took ef­fect on 1 Janu­ary 2018. They are aimed at im­prov­ing the mar­ket for pub­lic pro­cure­ment of medi­cines through the ad­op­tion.